However, EECs and the hormones they produce are candidate targets for drug development, as highlighted by the success of therapies based on Glucagon-like peptide-1 (GLP-1) for the treatment of type 2 diabetes and obesity. Here, GCG is linked to type 2 diabetes mellitus.